Patterns of Recurrence Following Complete Response to Regional Chemotherapy for In-Transit Melanoma
Department of Surgery, Duke University Medical Center, Durham, NC, USA. Annals of Surgical Oncology
(Impact Factor: 3.93).
04/2012; 19(8):2563-71. DOI: 10.1245/s10434-012-2315-5
Even after complete response (CR) to regional chemotherapy for in-transit melanoma, many patients develop recurrence. Understanding the probability, location, and timing of recurrences can optimize management strategies for this patient population.
A prospective database identified patients who underwent 81 first-time hyperthermic isolated limb perfusions (HILPs) and 133 first-time isolated limb infusions (ILIs). Response was defined using the response evaluation criteria in solid tumors; recurrence was defined as development of new disease after in-field CR.
HILP exhibited a significantly higher CR rate than ILI (44 vs. 28 %, p = .01). Among 36 HILP-CRs and 37 ILI-CRs, the 3-year recurrence rate was 65 % (95 % confidence interval [95 % CI]: 43-79 %) and 85 % (95 % CI: 63-94%), respectively. Median time to first recurrence was longer for HILP-CR than ILI-CR (23 vs. 8 months, p = .02). There was no statistically significant difference in median time to in-field recurrence between HILP-CR and ILI-CR (46 vs. 25 months, p = .15), but HILP-CR showed a longer median time to out-of-field recurrence (42 vs. 14 months, p = .02). Finally, the overall survival (OS) difference between HILP-CR and ILI-CR (3-year survival: 77 vs. 54 %) did not achieve statistical significance (p = .10).
In the largest series comparing patterns of recurrence, we demonstrate that out-of-field recurrence after CR to HILP occurs later than after CR to ILI, though control of in-field disease remains similar. There remains no statistically significant difference in overall survival after CR to the 2 procedures.
Available from: Eugenia (Jinny) Cho
[Show abstract] [Hide abstract]
ABSTRACT: To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infused melphalan (LPAM).
After treatment with systemic bevacizumab or saline, changes in vascular permeability were determined by spectrophotometric analysis of tumors infused with Evan's blue dye. Changes in vascular structure and tumor hemoglobin-oxygen saturation HbO(2) were determined by intravital microscopy and diffuse reflectance spectroscopy, respectively. Rats bearing the low-VEGF secreting DM738 and the high-VEGF secreting DM443 melanoma xenografts underwent isolated limb infusion (ILI) with melphalan (LPAM) or saline via the femoral vessels. The effect of bevacizumab on terminal drug delivery was determined by immunohistochemical analysis of LPAM-DNA adducts in tumor tissues.
Single-dose bevacizumab given three days before ILI with LPAM significantly decreased vascular permeability (50.3% in DM443, P < 0.01 and 35% in DM738, P < 0.01) and interstitial fluid pressure (57% in DM443, P < 0.01 and 50% in DM738, P = 0.01). HbO(2) decreased from baseline in mice following treatment with bevacizumab. Systemic bevacizumab significantly enhanced tumor response to ILI with LPAM in two melanoma xenografts, DM443 and DM738, increasing quadrupling time 37% and 113%, respectively (P = 0.03). Immunohistochemical analyses of tumor specimens showed that pretreatment with systemic bevacizumab markedly increased LPAM-DNA adduct formation.
Systemic treatment with bevacizumab before regional chemotherapy increases delivery of LPAM to tumor cells and represents a novel way to augment response to regional therapy for advanced extremity melanoma.
Clinical Cancer Research 04/2012; 18(12):3328-39. DOI:10.1158/1078-0432.CCR-11-3000 · 8.72 Impact Factor
[Show abstract] [Hide abstract]
Even after negative sentinel lymph node biopsy (SLNB) for primary melanoma, patients who develop in-transit melanoma (ITM) or local recurrences (LR) may have subclinical regional lymph node involvement.
A prospective database identified 33 patients with ITM/LR who underwent Tc-99m sulfur colloid lymphoscintography (LS) alone (n=15) or in conjunction with lymphazurin dye (n=18) administered only if the ITM/LR was concurrently excised.
Seventy nine percent (26/33) of patients undergoing SLNB in this study had prior removal of LNs in the same lymph node basin as the expected drainage of the IT or LR at the time of diagnosis of their primary melanoma. LS at time of presentation with ITM/LR was successful in 94% (31/33) cases, and at least one SLN was found intraoperatively in 97% (30/31) cases. The SLNB was positive in 33% (10/30) of these cases. Completion LN dissection was performed in 90% (9/10) of cases. Nine patients with negative SLNB and ITM underwent regional chemotherapy. Patients in this study with a positive SLN at the time the IT/LR was mapped had a significantly shorter time to the development of distant metastatic disease compared to those with negative SLNs.
In this study, we demonstrate the technical feasibility and clinical utility of repeat SLNB for recurrent melanoma. Performing SLNB can not only optimize local, regional, and systemic treatment strategies for patients with LR or ITM but also appears to provide important prognostic information.
Journal of the American College of Surgeons 01/2013; 218(4). DOI:10.1016/j.jamcollsurg.2013.12.025 · 5.12 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: IMPORTANCE Although approximately 30% to 50% of patients experience a complete response after regional chemotherapy for in-transit melanoma, a subset of patients will develop rapidly progressive disease. In the current era of an expanding armamentarium, including both regional and systemic options for treating advanced melanoma, identifying perioperative factors that predict disease progression may obviate unnecessary morbidity associated with regional therapy and avoid delays in systemic therapy. OBJECTIVE To identify patient-related clinical and pathological variables, as well as procedural factors, that correlate with disease progression. DESIGN Using a prospectively maintained database, we identified patients who either underwent first-time melphalan-based isolated limb infusion (ILI) or first-time hyperthermic isolated limb perfusion (HILP) for in-transit melanoma. Response was defined using modified Response Evaluation Criteria in Solid Tumors for cutaneous disease at 3 months after treatment. Survival analyses were performed using the Kaplan-Meier method, with the differences in survival curves compared using a log-rank test. Potential preoperative and procedural predictors of in-field progressive disease were analyzed using logistic regression. PARTICIPANTS Of the 258 patients included in the database, 215 were identified as having undergone first-time regional therapy. Of these 215 patients, 134 underwent ILI, and 81 underwent HILP. EXPOSURE Regional therapy (ILI or HILP). MAIN OUTCOMES AND MEASURES Complete response or progressive disease. RESULTS Of 134 patients who underwent ILI, 43 (32.1%) experienced in-field progressive disease. Of 81 patients who underwent HILP, 9 (11.1%) experienced in-field progressive disease. The median survival for patients with in-field progressive disease was 20.3 months for the ILI cohort and 15.0 months for the HILP cohort. In general, patients with progressive disease were younger, with advanced-stage melanoma and increased tumor burden. Compared with patients who experienced a complete response, patients with in-field progressive disease after ILI were younger (odds ratio, 1.06 [95% CI, 0.90-0.98]; P = .002). For patients who underwent HILP, no clinically relevant preoperative predictors of in-field progressive disease were identified. Procedural variables, including chemotherapeutic dosing, degree of acidosis or base deficit achieved, and peak temperature attained, were not predictors of in-field progressive disease after ILI or HILP. CONCLUSIONS AND RELEVANCE Patient, clinical, and procedural factors are unreliable predictors of in-field progressive disease after regional therapy in patients with in-transit melanoma. Defining the potential utility of molecular markers in predicting response or failure of regional therapy should be the focus of future research efforts.
JAMA SURGERY 04/2013; 148(6):1-6. DOI:10.1001/jamasurg.2013.695 · 3.94 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.